{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:46:29Z","timestamp":1791254789599,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.msard.2018.12.014","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T12:50:24Z","timestamp":1544791824000},"page":"81-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Multiple sclerosis and cancer incidence: A Danish nationwide cohort study"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-5891","authenticated-orcid":false,"given":"M.","family":"N\u00f8rgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Veres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Didden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wormser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2018.12.014_bib0001","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-004-2229-4","article-title":"Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments","volume":"89","author":"Achiron","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"issue":"13","key":"10.1016\/j.msard.2018.12.014_bib0002","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/01.wnl.0000345366.10455.62","article-title":"Cancer risk among patients with multiple sclerosis and their parents","volume":"72","author":"Bahmanyar","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2018.12.014_bib0003","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.msard.2015.08.005","article-title":"Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database","volume":"4","author":"Capkun","year":"2015","journal-title":"Multiple Scler. Related Disord."},{"issue":"5","key":"10.1016\/j.msard.2018.12.014_bib0004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic. Dis."},{"key":"10.1016\/j.msard.2018.12.014_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2016.09.005","article-title":"Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk","volume":"370","author":"Gaindh","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2018.12.014_bib0006","series-title":"Multiple Sclerosis: Perspectives in Treatment and Pathogenesis","article-title":"Living with multiple sclerosis in europe: pharmacological treatments, cost of illness, and health-related quality of life across countries","author":"Gitto","year":"2017"},{"issue":"7 Suppl","key":"10.1016\/j.msard.2018.12.014_bib0008","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish cancer registry","volume":"39","author":"Gjerstorff","year":"2011","journal-title":"Scand. J. Public Health"},{"issue":"3","key":"10.1016\/j.msard.2018.12.014_bib0009","first-page":"175","article-title":"Multiple sclerosis review","volume":"37","author":"Goldenberg","year":"2012","journal-title":"P & T"},{"issue":"7 Suppl","key":"10.1016\/j.msard.2018.12.014_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1403494811399958","article-title":"The Danish register of causes of death","volume":"39","author":"Helweg-Larsen","year":"2011","journal-title":"Scand. J. Public Health"},{"issue":"2","key":"10.1016\/j.msard.2018.12.014_bib0011","first-page":"419","article-title":"Mortality in Danish patients with nonmelanoma skin cancer, 1978-2001","volume":"159","author":"Jensen","year":"2008","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.msard.2018.12.014_bib0012","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cdp.2007.04.011","article-title":"Do incident and new subsequent cases of non-melanoma skin cancer registered in a Danish prospective cohort study have different 10-year mortality?","volume":"31","author":"Jensen","year":"2007","journal-title":"Cancer Detect. Prev."},{"issue":"Pt 10","key":"10.1016\/j.msard.2018.12.014_bib0013","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/brain\/aws148","article-title":"Cancer risk in multiple sclerosis: findings from British Columbia, Canada","volume":"135","author":"Kingwell","year":"2012","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.msard.2018.12.014_bib0014","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/jnnp-2013-307238","article-title":"Assessment of cancer risk with beta-interferon treatment for multiple sclerosis","volume":"85","author":"Kingwell","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2018.12.014_bib0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0404.1988.tb03672.x","article-title":"Epidemiology of multiple sclerosis: incidence and prevalence rates in Denmark 1948-64 based on the Danish Multiple Sclerosis Registry","volume":"78","author":"Koch-Henriksen","year":"1988","journal-title":"Acta Neurol. Scand."},{"issue":"199","key":"10.1016\/j.msard.2018.12.014_bib0016","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ane.12424","article-title":"Registers of multiple sclerosis in Denmark","volume":"132","author":"Koch-Henriksen","year":"2015","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.msard.2018.12.014_bib0017","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1352458507083625","article-title":"Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis","volume":"14","author":"Lebrun","year":"2008","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2018.12.014_bib0018","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.msard.2018.12.014_bib0019","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00415-011-5929-9","article-title":"Cancer and multiple sclerosis in the era of disease-modifying treatments","volume":"258","author":"Lebrun","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.12.014_bib0020","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2147\/CLEP.S99500","article-title":"The danish multiple sclerosis treatment register","volume":"8","author":"Magyari","year":"2016","journal-title":"Clin. Epidemiol."},{"issue":"6","key":"10.1016\/j.msard.2018.12.014_bib0021","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0404.1996.tb00019.x","article-title":"Multiple sclerosis and cancer in Norway. A retrospective cohort study","volume":"93","author":"Midgard","year":"1996","journal-title":"Acta neurologica Scandinavica"},{"issue":"11","key":"10.1016\/j.msard.2018.12.014_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188120","article-title":"Decreased prevalence of cancer in patients with multiple sclerosis: a case-control study","volume":"12","author":"Moisset","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.msard.2018.12.014_bib0023","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0404.1991.tb04941.x","article-title":"Cancer incidence following hospitalization for multiple sclerosis in Denmark","volume":"84","author":"Moller","year":"1991","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.msard.2018.12.014_bib0024","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2018.12.014_bib0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11357-011-9255-z","article-title":"Hormonal determinants and effect of ER22\/23EK glucocorticoid receptor gene polymorphism on health status deterioration in the participants of the Mataro Ageing Study","volume":"34","author":"Mora","year":"2012","journal-title":"Age (Dordrecht, Netherlands)"},{"issue":"4","key":"10.1016\/j.msard.2018.12.014_bib0026","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.21437","article-title":"Cancer risk among patients with multiple sclerosis: a population-based register study","volume":"118","author":"Nielsen","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.msard.2018.12.014_bib0027","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","article-title":"No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine","volume":"2","author":"Pakpoor","year":"2015","journal-title":"Neurology(R) Neuroimmunol. Neuroinflam."},{"issue":"8","key":"10.1016\/j.msard.2018.12.014_bib0028","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.msard.2018.12.014_bib0029","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish national patient registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin. Epidemiol."},{"issue":"5","key":"10.1016\/j.msard.2018.12.014_bib0030","first-page":"535","article-title":"The Danish Cancer Registry\u2013history, content, quality and use","volume":"44","author":"Storm","year":"1997","journal-title":"Dan. Med. Bull."},{"key":"10.1016\/j.msard.2018.12.014_bib0031","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2288-11-83","article-title":"The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish national registry of patients","volume":"11","author":"Thygesen","year":"2011","journal-title":"BMC Med. Res. Method."},{"issue":"3","key":"10.1016\/j.msard.2018.12.014_bib0032","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0300-483X(02)00612-1","article-title":"Immunosuppressive drugs and cancer","volume":"185","author":"Vial","year":"2003","journal-title":"Toxicology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:46:04Z","timestamp":1761900364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818305431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":31,"alternative-id":["S2211034818305431"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.014","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple sclerosis and cancer incidence: A Danish nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}